Several studies have indicated that oxidative stress is a major risk factor for the initiation and progression of neurological disorders like Parkinson's disease (PD) and Alzheimer's (AD). Therefore, reducing oxidative stress appears to be a rational choice for the prevention and reduction in the rate of progression of these neurological disorders. The brain utilizes about 25% of respired oxygen even though it represents only 5% of the body weight. Free radicals are generated during the normal intake of oxygen, during infection, and during normal oxidative metabolism of certain substrates. Although experimental data are consistent in demonstrating the neuroprotective effects of antioxidants in vitro and in animal models, the clinical evidence that antioxidant agents may prevent or slow the course of these diseases is still relatively unsatisfactory, and insufficient to strongly modify clinical practice.
In this paper, natural possible substances that could be added to a beverage to prevent or decrease the developing of neurodegenerative diseases are reviewed.
KedarNP. (2003) Can We prevent Parkinson's and Alzheimer's disease?Journal of Postgraduate in Medicine, 49, 236–245.
5.
PackerL, WeberSU, RimbachG. (2001) Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling, The Journal of Nutrition, 131, 369S–73S.
6.
TraberMG, AtkinsonJ. (2007) Vitamin E, antioxidant and nothing more. Free Radical Biological Medicine, 43, 4–15.
7.
U.S. Department of Agriculture, Agricultural Research Service. (2004) USDA National Nutrient Database for Standard Reference, Release 16-1. Nutrient Data Laboratory Home.
8.
MeisterA (1994) Glutathione-ascorbic acid antioxidant system in animals. Journal of Biological Chemistry, 269, 9397–9400.
9.
LinderMC. (1991) Food quality and its determinants from field to table growing food, its storage and preparation, Chapter 10. In: LinderM (ed) Nutritional Biochemistry and Metabolism with Clinical Applications, Elsevier, New York, London; 239–254.
10.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal Medicine, 352, 2379–2388.
11.
VileGF, WinterbournCC. (1988) Inhibition of adriamycin-promoted microsomal lipid peroxidation by beta-carotene, alpha-tocopherol and retinol at high and low oxygen partial pressures. FEBS Letters, 238, 353–356.
12.
GoodmanY, MattsonMP. (1994) Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Experimental Neurology, 128, 1–12.
13.
ArltS, Müller-ThomsenT, BeisiegelU. (2002) Use of vitamin C and E in the treatment of Alzheimer's disease. Drug Development Research, 56, 452–457.
14.
KontushK, SchekatolinaS. (2004) Vitamin E in neurodegenerative disorders: Alzheimer's disease. Annals of the New York Academy of Sciences, 1031, 249–262.
15.
FukuiK, OmoiNO, HayasakaT, ShinnkaiT, SuzukiS, AbeK, UranoS. (2002) Cognitive impairment of rats caused by oxidative stress and aging, and its prevention by vitamin E. Annals of the New York Academy of Sciences, 95, 275–284.
16.
PillaiSR, TraberMG, SteissJE, KaydenHJ, CoxNR. (1993) Alpha-tocopherol concentrations of the nervous system and selected tissues of adult dogs fed three levels of vitamin E. Lipids, 28, 1101–1105.
17.
MartinA, CuervoA, DiceJ, JosephJ. (2000) Effect of vitamin C on intracellular protein turnover in human glial cells. Presented at Society for Neuroscience Annual Meeting: 1830a.
18.
SanoM, ErnestoC, ThomasRG, KlauberMR, SchaferK, GrundmanM, WoodburyP, GrowdonJ, CotmanCW, PfeifferE, SchneiderLS, ThalLJ. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal Medicine, 336, 1216–1222.
19.
GrundmanM. (2000) Vitamin E and Alzheimer disease: the basis for additional clinical trials1,2,3. American Journal of Clinical Nutrition, 71, 630S–636S.
20.
IsaacMgekn, QuinnR, TabetN. (2008) Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews, Issue 4. John Wiley & Sons, LtdChichester, UK DOI:10.1002/14651858. CD002854
21.
O'hareE, McDiadD, WilsonR, KennedyF, KimE. (2000) Chronic alpha-tocopherol administrtion protects against behavioral impairment induced following intra-hipocampal Aß injection. Presented at Society for Neuroscience Annual Meeting: 1788a.
22.
MasakiKH, LosonczyKG, IzmirlianG, FoleyDJ, RossGW, PetrovitchH, HavlikR, WhiteLR. (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 54, 1265–1272.
23.
EngelhartMJ, GeerlingsMI, RuitenbergA, van SwietenJC, HofmanA, WittemanJC, BretelerMM. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. Journal of the American Medical Association, 287, 3223–3229.
24.
MorrisMC, BeckettLA, ScherrPA, HebertLE, BennettDA, FieldTS, EvansDA. (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Disease & Associated Disorder, 12, 121–126.
25.
MorrisMC, EvansDA, BieniasJL, TangneyCC, BennettDA, AggarwalN, WilsonRS, ScherrPA. (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracialcommunity study. Journal of the American Medical Association, 287, 3230–3237.
26.
PhamDQ, PlakogiannisR. (2005) Vitamin E Supplementation in cardiovascular disease and cancer prevention: Part 1 The Annals of Pharmacotherapy, 39, 1870–1888.
27.
BoothbyLA, DoeringPL. (2004) Vitamin C and vitamin E for Alzheimer's disease, The Annals of Pharmacotherapy, 39, 2073–2080.
28.
FillenbaumGG, MaragathaNK, HanlonJT, ArtzMB, PieperCF, SchmaderKE, DyskenMW, MD, GraySL. (2005) Dementia and Alzheimer's Disease in community-dwelling elders taking vitamin C and/or vitamin E. The Annals of Pharmacotherapy, 39, 2009–2014.
29.
EtminanM, GillSS, SamiiA. (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurology, 4, 362–365.
30.
RamassamyC. (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. European Journal of Pharmacology, 545, 51–64
31.
KyleJ, DuthieG. (2006) Nutritional relevance of flavonoids in disease prevention. Natural Product Communications, 1, 1049–1060.
32.
SinghM, ArseneaultM, SandersonT, MurthyV, RamassamyC. (2008) Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. Journal of Agricultural and Food Chemistry, 56, 4855–4873.
33.
KroonPA, CliffordMN, CrozierA. (2004) How should we assess the effects of exposure to dietary polyphenols in vitro?American Journal Clinical Nutrition, 80, 15–21.
34.
Rice-EvansCA, MillerNJ. (1996) Paganga G. Structure- antioxidant actiivity relationships of flavonoids and phenolics acids. Free Radical Biology and Medicine, 20, 993–956.
35.
ScalbertA, WilliamsonG. (2000) Dietary intake and bioavailability of polyphenols. Journal Nutrition, 130, 2073S–85S.
36.
ManachC, WilliamsonG, ScalbertA, RémésyC. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. American Journal Clinical Nutrition, 81S, 230–242.
37.
ManachC, ScalbertA, MorandC, RémésyC, JiménezL. (2004) Polyphenols: food sources and 97 bioavailability studies. American Journal Clinical Nutrition, 79, 727–747.
38.
MoonJH, NakataR, OshimaS, InakumaT, TeraoJ. (2000) Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. American Journal of Physiology-Regulatory, Integrative, and Comparative Physiology, 279, 461R–467R.
39.
ZhangY, SongTT, CunnickJE, MurphyPA, HendrichS. (1999) Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. Journal Nutrition, 129, 399–405.
40.
SpencerJP, SchroeterH, CrossthwaitheAJ, KuhnleG, WilliamsRJ, Rice-EvansC. (2001) Contrasting influences of glucuronidation and o-methylation of epicathechin on hydrogen peroxide-induced cell death in neurons and fibroblasts. Free Radical Biology and Medicine, 31, 1139–1146.
41.
SuganumaM, OkabeS, OniyamaM, TadaY, ItoH, FujikiH. (1998) Wide distribution of (-) epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis, 19, 1771–1776.
42.
YoudimKA, DobbieMS, KuhnleG, ProteggenteAR, AbbottNJ, Rice-EvansC. (2003) Interaction between flavonoids and the blood – brain barrier: in vitro studies. Journal of Neurochemistry, 85, 180–192.
43.
LetenneurL, Proust-LimaC, Le GougeA, DartiguesJ, Barberger-GateauP. (2007) Flavonoid intake an cognitive decline over a 10-year period. American Journal of Epidemiology, 165, 1364–1371.
44.
BastianettoS, YaoZ, PapadopoulosV, QuirionR. (2006) Neuro protective effects of green and black teas and their catechin gallate esters against β-amyloid induced toxicity. European Journal of Neuroscience, 23, 55–64.
45.
LauFC, Shukitt-HaleB, JosephJA. (2005) The beneficial effects of fruit polyphenols on brain aging. Neurobiology of Aging, 26(S1), 128–132.
46.
WangJ, HoL, ZhaoW, OnoK, RosensweigC, ChenL, HumalaN, TeplowDB, PasinettiGM. (2008) Moderate consumption of Cabernet Sauvignon attenuates Aß neuropathology in a mouse model of Alzheimer's disease. Journal of Neurosciencce, 28, 6388–6392.
MiquelJ, BerndA, SempereJM, Díaz-AlperiJ, RamírezA. (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Archives of Gerontology and Geriatrics, 34, 37–46
49.
AliBH, MarrifH, NoureldayemSA, BakheitAO, BlundenG. (2006) Some biological properties of curcumin: a review. Natural Product Communications, 1, 509–521.
50.
AmmonHP, SafayhiH, MackT, SabierajJ. (1993) Mechanism of anti-inflammatory actions of curcumine and boswellic acids. Journal of Ethnopharmacology, 38, 113–119.
51.
OnoK, YoshiikeY, TakashimaA, HasegawaK, NaikiH, YamadaM. (2003) Potent antiamyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. Journal of Neurochemistry, 87, 172–181.
52.
AnekondaTS. (2006) Resveratrol-a boon for treating Alzheimer's disease?Brain research reviews, 52, 316–326.
53.
SharmaM, GuptaY.K. (2002) Chronic treatment with trans-resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sciences, 71, 2489–2498.
54.
BlanchetJ, LongpréF, BureauG, MorissetteM, DiPaoloT, BronchtiG, MartinoliMG. (2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1243–1250
55.
SurYJ, SurhYJ. (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radical Biology and Medicine, 34, 1100–1110.
56.
CarluccioMA, SiculellaL, AncoraMA, MassaroM, ScodittiE, StorelliC, CarluccioM., DistanteA., De CaterinaR (2003) Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 622–629.
57.
SavaskanE, OlivieriG, MeierF, SeifritzE, Wirz-JusticeA, Müller-SpahnF. (2003) Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology, 49, 380–383
58.
DiplockAT. (1992) Selenium, antioxidant nutritions, and human diseases. Biological Trace Element Research, 33, 155–156.
59.
ChenJ, MarlaB. (2003) Selenium and selenoproteins in the brain and brain diseases. Journal of Neurochemistry, 86, 1–12.
60.
RinkL, GabrielP. (2000) Zinc and the immune system. Proceedings of the Nutrition Society, 59, 541–552.
61.
SandstromB. (1997) Bioavailability of zinc. Proceedings of the Nutrition Society, 51, S17–S19.
62.
WiseA. (1995) Phytate and zinc bioavailability. International Journal of Food Sciences and Nutrition, 46, 53–63.
63.
TownerRA, ApplebyC, LevyM, BrayTM. (2004) Zinc deficiency and oxidative stress in brain: Magnetic resonance investigations in weanling rats. The Journal of Trace Elements in Experimental Medicine, 17, 161–174.
64.
ShultsCW. (2003) Coenzyme Q10 in neurodegenerative diseases. Current Medicinal Chemistry, 10, 1917–1921.
65.
WhelanJ, RustC. (2006) Innovative dietary sources of n-3 fatty acids. Annual Review of Nutrition, 26, 75–103.
66.
SatohN, ShumatsuA, KotaniK, SakaneN, YamadaK, SuganamiT, KuzuyaH, OgawaY. (2007) Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care, 30, 144–146.
67.
GrielAE, Kris-EthertonPM, HilpertKF, ZhaoG, WestSG, CorwinRL. (2007) An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutrition Journal, 6, 2–10.
68.
SeverusWE, LittmanAB, StollAL. (2001) Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. Harvard Review of Psychiatry, 9, 280–293.
69.
MantziorisE, ClelandLG, GibsonRA, NeumannMA, DemasiM, JamesMJ. (2000) Biochemical effects of a diet containing foods enriched with n-3 fatty acids. American Journal of Clinical Nutrition, 72, 42–48.
Kris-EthertonPM, HarrisWS, AppelLJ. (2003) Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 151–152.
72.
Kris-EthertonPM, HarrisWS, AppelLJ. (2003) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, e20–e30.
73.
HarrisWS, AssaadB, PostonWC. (2006) Tissue omega-6/omega-3 fatty acid ratio and risk for coronary artery disease. American Journal of Cardiology, 98, 19i–26i.
74.
CalonF, ColeG. (2007) Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins, Leucotrienes and essential fatty acids Prostaglandins, 77, 287–293.
75.
JulienC, TremblayC, PhivilayA, BerthiaumeL, EmondV, JulienP, CalonF. (2008) High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiology of Aging, in press.
76.
BousquetM, Saint-PierreM, JulienC, SalemN, CicchettiJF, CalonF. (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Journal of the Federation of American Societies for Experimental Biology, 22, 1213–1225.
77.
YehudaS, RabinovtzS, CarassoRL, MostofskyDI. (1996) Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. International Journal of Neuroscience, 87, 141–149.
78.
TeranoT, FujishiroS, BanT, YamamotoK, TanakaT, NoguchiY, TamuraY, YazawaK, HirayamaT. (1999) Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids, 34, S345–S346.
79.
PeersRJ. (1990) Alzheimer's disease and omega-3 fatty acids: hypothesis. Medical Journal, 153, 563–564.
80.
SearsB. (2002) The Omega Rx Zone.Harper-Collins, New York.
81.
ReedLJ. (2001) A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. Journal of Biological Chemistry, 276, 38329–38336.
82.
SmithAR, ShenviSV, WidlanskyM, SuhJH, HagenTM. (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medicinal Chemistry, 11, 1135–1146.
83.
KramerK, PackerL. (2001) R-alpha-lipoic acid. In: KramerK, HoppeP, PackerL, eds. Nutraceuticals in health and disease prevention.New York: Marcel Dekker, Inc.129–164.
84.
JonesW, LiX, QuZC, PerriottL, WhitesellRR, MayJM. (2002) Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radical Biology and Medicine, 33, 83–93.
85.
MayJM, QuZC, MendirattaS. (1998) Protection and recycling of alpha-tocopherol in human erythrocytes by intracellular ascorbic acid. Archives of Biochemistry and Biophysics, 349, 281–289.
86.
KozlovAV, GilleL, StaniekK, NohlH. (1999) Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Archives of Biochemistry and Biophysics, 63, 148–154.
87.
UpstonJM, TerentisAC, StockerR. (1999) Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. Journal of the Federation of American Societies for Experimental Biology, 13, 977–994.
88.
HagenTM, LiuJ, LykkesfeldtJ, WehrCM, IngersollRT, VinarskyV, BartholomewJC, AmesBN. (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 99, 1870–1875.
89.
LiuJ, HeadE, GharibAM, YuanW, IngersollRT, HagenTM, CotmanCW, AmesBN. (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proceedings of the National Academy of Sciences of the United States of America, 99, 2356–2361.
90.
FarrSA, PoonHF, Dogrukol-AkD, DrakeJ, BanksWA, EyermanE, ButterfieldDA, MorleyJE. (2003) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of Neurochemistry, 84, 1173–1183.
91.
MilgramNW, HeadE, ZickerSC, Ikeda-DouglasCJ, MurpheyH, MuggenburgB, SiwakC, TappD, CotmanCW. (2005) Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiology Aging, 26, 77–90.
92.
SeshadriS, BeiserA, SelhubJ, JacquesPF, RosenbergIH, D'AgostinoRB, WilsonPW, WolfPA. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England Journal of Medicine, 346, 476–483.
93.
WhyteEM, MulsantBH, ButtersMA, QayyumM, TowersA, SweetRA, KlunkW, WisniewskiS, DeKoskyST. (2002) Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. American Journal of Geriatry and Psychiatry, 10, 321–327.
94.
JohnsonMA, HawthorneNA, BrackettWR, FischerJG, GunterEW, AllenRH, StablerSP. (2003) Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. American Journal of Clinical Nutrition, 77, 211–220.
95.
WangHX, WahlinA, BasunH, FastbomJ, WinbladB, FratiglioniL. (2001) Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology, 56, 1188–1194.
96.
ClarkeR, SmithAD, JobstKA, RefsumH, SuttonL, UelandPM. (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology, 55, 1449–1455.
97.
SnowdonDA, TullyCL, SmithCD, RileyKP, MarkesberyWR. (2000) Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. American Journal of Clinical Nutrition, 71, 993–998.
98.
MillerJ W. (2002) Vitamin B12 deficiency, tumor necrosis factor-alpha, and epidermal growth factor: a novel function for vitamin B12?Nutrition Reviews, 60, 142–144.
99.
WeirDG, MolloyA. (2000) Microvascular disease and dementia in the elderly: are they related to hyperhomocysteinemia. American Journal of Clinical Nutrition, 71, 859–860.
100.
AbyadA. (2002) Prevalence of Vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement, Journal of Nutrition Health Aging, 6, 254–260.
101.
EastleyR, WilcockGK, BucksRS. (2000) Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. International Journal of Geriatric and Psychiatry, 15, 226–233.
102.
KuzminskiAM, Del GiaccoEJ, AllenRH, StablerSP, LindenbaumJ. (1998) Effective treatment of cobalamin deficiency with oral cobalamin. Blood, 92, 1191–1198.
103.
TanakaM, MachidaY, NiuS, IkedaT, JanaNR, DoiH, KurosawaM, NekookiM, NukinaN. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nature Medicine, 10, 148–154.
104.
DaviesJ E, SarkarS, RubinszteinDC. (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Human Molecular Genetics, 15, 23–31.
105.
LiuR, BarkhordarianH, EmadiS, ParkCB, SierksMR. (2005) Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiology Disease, 20, 74–81.
RitchieK, CarrièreI, de MendonaA, PortetF, DartiguesJF, RouaudO, Barberger-GateauP, AncelinML. (2007) The neuroprotective effects of caffeine. A prospective population study (the Three City Study), Neurology, 69, 536–545.
108.
ChenX, GawrylukJW, WagenerJF, GhribiO, GeigerJD. (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. Journal of Neuroinflammation, 5, 1–14.
109.
WuJN, HoSC, ZhouC, LingWH, ChenWQ, WangCL, ChenYM. (2008) Coffee consumption and risk of coronary heart diseases: A meta-analysis of 21 prospective cohort studies. International Journal of Cardiology, Aug 14.
110.
SolomonPR, AdamsF, SilverA, ZimmerJ, DeVeauxR. (2002) Ginkgo for memory enhancement: a randomized controlled trial, Journal of the American Medical Association, 288, 835–840.
111.
FotuhiM. (2003) The Memory Cure. New York, McGraw Hill.
112.
BirksJ, GrimleyEV, Van DongenM. (2002) Ginkgo biloba for cognitive impairment and dementia. Cochrane.Database. System Review. No. 4, CD003120.
113.
LuoY, SmithJV, ParamasivamV, BurdickA, CurryKJ, BufordJP, KhanI, NetzerWJ, XuH., ButkoP. (2002) Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proceedings of the National Academy of Sciences of the United States of America, 99, 12197–12202.
114.
AndrieuS, GilletteS, AmouyalK, NourhashemiF, ReynishE, OussetPJ, AlbaredeJL, VellasB, GrandjeanH. (2003) Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 58, 372–377.
